A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

NCT03192345 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumor

Interventions

BIOLOGICAL: SAR439459
DRUG: Cemiplimab REGN2810

Sponsor

Sanofi